Inovio Pharmaceuticals (INO) filed a shelf registration to offer up to $300 million in a mix of securities, including common and preferred stock, debt securities, and warrants.
Proceeds may be used for working capital, capital expenditures, general corporate purposes, and potential acquisitions, the company said Thursday in a regulatory filing.